Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q13443
UPID:
ADAM9_HUMAN
Alternative names:
Cellular disintegrin-related protein; Meltrin-gamma; Metalloprotease/disintegrin/cysteine-rich protein 9; Myeloma cell metalloproteinase
Alternative UPACC:
Q13443; B7ZLN7; Q10718; Q8NFM6
Background:
Disintegrin and metalloproteinase domain-containing protein 9, also known as Meltrin-gamma and Myeloma cell metalloproteinase, plays a pivotal role in tumorigenesis and angiogenesis. It cleaves molecules like TEK, KDR, and VCAM1, influencing cell interactions and motility. Additionally, it may function as alpha-secretase for amyloid precursor protein, impacting neurodegenerative processes.
Therapeutic significance:
Linked to Cone-rod dystrophy 9, a retinal disorder with early vision loss, understanding Disintegrin and metalloproteinase domain-containing protein 9's role could unveil new therapeutic avenues.